Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180162 · ClinicalTrials.gov registry record · Phase 1
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
A Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05180162: Completed Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis, sponsored by Thomas Hope.
NCT05180162 is a Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis that has completed, run by Thomas Hope. The registered enrollment target is 16 participants, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05180162, a Phase 1 study of Pulmonary Fibrosis and Liver Fibrosis, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.
Primary Outcome
Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.
Conditions Studied
Interventions
- DRUG 68Ga-FAP-2286
- PROCEDURE Positron Emission Tomography (PET)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 1 |
What the finished NCT05180162 record still lists
NCT05180162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 888-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which 68Ga-FAP-2286 is the first listed.
NCT05180162 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05180162 about?
NCT05180162 is a clinical study titled "Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286". This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP...
What is the current status of trial NCT05180162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-12-09. Estimated completion is 2024-05-28.
What conditions does trial NCT05180162 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis, Liver Fibrosis, Myocardial Fibrosis.
What interventions are being tested in trial NCT05180162?
The interventions under investigation include: 68Ga-FAP-2286 (DRUG), Positron Emission Tomography (PET) (PROCEDURE).
Who is sponsoring clinical trial NCT05180162?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05180162 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05180162's enrollment target sits among peer trials
16 21st of 22 higher than 2 of 22 other Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
RECRUITING · Phase 1
-
A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
COMPLETED · Phase 1
-
Advanced Imaging for Pulmonary Fibrosis
RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
FAPI PET for Lung Fibrosis
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI